{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T02:38:44Z","timestamp":1768271924895,"version":"3.49.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,11,24]],"date-time":"2024-11-24T00:00:00Z","timestamp":1732406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,24]],"date-time":"2024-11-24T00:00:00Z","timestamp":1732406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Vessels"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s00380-024-02489-0","type":"journal-article","created":{"date-parts":[[2024,11,24]],"date-time":"2024-11-24T13:51:34Z","timestamp":1732456294000},"page":"496-508","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Long-term clinical outcomes after alcohol septal ablation for hypertrophic obstructive cardiomyopathy in Japan: a retrospective study"],"prefix":"10.1007","volume":"40","author":[{"given":"Junya","family":"Matsuda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8821-4884","authenticated-orcid":false,"given":"Hitoshi","family":"Takano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoichi","family":"Imori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kakeru","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideto","family":"Sangen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Nakata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Miyachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Hosokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuhei","family":"Tara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukichi","family":"Tokita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsunobu","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morimasa","family":"Takayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuniya","family":"Asai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,24]]},"reference":[{"key":"2489_CR1","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","volume":"44","author":"E Arbelo","year":"2023","unstructured":"Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C, Bezzina CR, Biagini E, Blom NA, de Boer RA, De Winter T, Elliott PM, Flather M, Garcia-Pavia P, Haugaa KH, Ingles J, Jurcut RO, Klaassen S, Limongelli G, Loeys B, Mogensen J, Olivotto I, Pantazis A, Sharma S, Van Tintelen JP, Ware JS, Kaski JP (2023) 2023 ESC guidelines for the management of cardiomyopathies. Eur Heart J 44:3503\u20133626","journal-title":"Eur Heart J"},{"key":"2489_CR2","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1253\/circj.CJ-20-0910","volume":"85","author":"H Kitaoka","year":"2021","unstructured":"Kitaoka H, Tsutsui H, Kubo T, Ide T, Chikamori T, Fukuda K, Fujino N, Higo T, Isobe M, Kamiya C, Kato S, Kihara Y, Kinugawa K, Kinugawa S, Kogaki S, Komuro I, Hagiwara N, Ono M, Maekawa Y, Makita S, Matsui Y, Matsushima S, Sakata Y, Sawa Y, Shimizu W, Teraoka K, Tsuchihashi-Makaya M, Ishibashi-Ueda H, Watanabe M, Yoshimura M, Fukusima A, Hida S, Hikoso S, Imamura T, Ishida H, Kawai M, Kitagawa T, Kohno T, Kurisu S, Nagata Y, Nakamura M, Morita H, Takano H, Shiga T, Takei Y, Yuasa S, Yamamoto T, Watanabe T, Akasaka T, Doi Y, Kimura T, Kitakaze M, Kosuge M, Takayama M, Tomoike H (2021) JCS\/JHFS 2018 guideline on the diagnosis and treatment of cardiomyopathies. Circ J 85:1590\u20131689","journal-title":"Circ J"},{"key":"2489_CR3","doi-asserted-by":"publisher","first-page":"e1239","DOI":"10.1161\/CIR.0000000000001250","volume":"149","author":"SR Ommen","year":"2024","unstructured":"Ommen SR, Ho CY, Asif IM, Balaji S, Burke MA, Day SM, Dearani JA, Epps KC, Evanovich L, Ferrari VA, Joglar JA, Khan SS, Kim JJ, Kittleson MM, Krittanawong C, Martinez MW, Mital S, Naidu SS, Saberi S, Semsarian C, Times S, Waldman CB (2024) 2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR Guideline for the management of hypertrophic cardiomyopathy: a report of the American heart association\/American college of cardiology joint committee on clinical practice guidelines. Circulation 149:e1239\u2013e1311","journal-title":"Circulation"},{"key":"2489_CR4","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1016\/j.jacc.2009.07.050","volume":"54","author":"BJ Maron","year":"2009","unstructured":"Maron BJ, Lever H (2009) In defense of antimicrobial prophylaxis for prevention of infective endocarditis in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 54:2339\u20132340","journal-title":"J Am Coll Cardiol"},{"key":"2489_CR5","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1161\/CIRCULATIONAHA.106.644682","volume":"114","author":"MS Maron","year":"2006","unstructured":"Maron MS, Olivotto I, Zenovich AG, Link MS, Pandian NG, Kuvin JT, Nistri S, Cecchi F, Udelson JE, Maron BJ (2006) Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation 114:2232\u20132239","journal-title":"Circulation"},{"key":"2489_CR6","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S0140-6736(95)91267-3","volume":"346","author":"U Sigwart","year":"1995","unstructured":"Sigwart U (1995) Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 346:211\u2013214","journal-title":"Lancet"},{"key":"2489_CR7","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jchf.2015.06.011","volume":"3","author":"M Liebregts","year":"2015","unstructured":"Liebregts M, Vriesendorp PA, Mahmoodi BK, Schinkel AFL, Michels M, Ten Berg JM (2015) A systematic review and meta-analysis of long-term outcomes after septal reduction therapy in patients with hypertrophic cardiomyopathy. JACC Heart Fail 3:896\u2013905","journal-title":"JACC Heart Fail"},{"key":"2489_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","volume":"28","author":"RM Lang","year":"2015","unstructured":"Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU (2015) Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European Association of cardiovascular imaging. J Am Soc Echocardiogr 28:1-39.e14","journal-title":"J Am Soc Echocardiogr"},{"key":"2489_CR9","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.jjcc.2021.11.023","volume":"80","author":"Y Maekawa","year":"2022","unstructured":"Maekawa Y, Takamisawa I, Takano H, Takayama M (2022) Percutaneous transluminal septal myocardial ablation: past, present, and future. J Cardiol 80:211\u2013217","journal-title":"J Cardiol"},{"key":"2489_CR10","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1001\/jama.1988.03720040031022","volume":"259","author":"J Cohn","year":"1988","unstructured":"Cohn J et al (1988) Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. JAMA 259:539\u2013544","journal-title":"JAMA"},{"key":"2489_CR11","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1093\/eurheartj\/ehz110","volume":"40","author":"J Veselka","year":"2019","unstructured":"Veselka J, Faber L, Liebregts M, Cooper R, Januska J, Kashtanov M, Dabrowski M, Hansen PR, Seggewiss H, Hansvenclova E, Bundgaard H, Ten Berg J, Stables RH, Jensen MK (2019) Short- and long-term outcomes of alcohol septal ablation for hypertrophic obstructive cardiomyopathy in patients with mild left ventricular hypertrophy: a propensity score matching analysis. Eur Heart J 40:1681\u20131687","journal-title":"Eur Heart J"},{"key":"2489_CR12","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/S0300-8932(03)77035-3","volume":"56","author":"S Rivera","year":"2003","unstructured":"Rivera S, Sitges M, Azqueta M, Marigliano A, Velamaz\u00e1n M, Miranda-Guardiola F, Betriu A, Par\u00e9 C (2003) Remodelado ventricular izquierdo tras ablaci\u00f3n septal percut\u00e1nea con alcohol en pacientes con micardiopat\u00eda hipertr\u00f3fica obstructiva: estudio ecocardiogr\u00e1fico [Left ventricular remodeling in patients with hypertrophic obstructive cardiomyopathy treated with percutaneous alcohol septal ablation: an echocardiographic study]. Rev Esp Cardiol 56:1174\u20131181","journal-title":"Rev Esp Cardiol"},{"key":"2489_CR13","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1007\/s00380-017-1053-9","volume":"33","author":"J Matsuda","year":"2018","unstructured":"Matsuda J, Kitamura M, Takayama M, Imori Y, Shibuya J, Kubota Y, Sangen H, Nakamura S, Takano H, Asai K, Shimizu W (2018) Chronic phase improvements in electrocardiographic and echocardiographic manifestations of left ventricular hypertrophy after alcohol septal ablation for drug-refractory hypertrophic obstructive cardiomyopathy. Heart Vessels 33:246\u2013254","journal-title":"Heart Vessels"},{"key":"2489_CR14","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.jchf.2022.06.009","volume":"10","author":"D Sun","year":"2022","unstructured":"Sun D, Schaff HV, Nishimura RA, Geske JB, Dearani JA, Ducharme MT, Ommen SR (2022) Posterior wall thickness associates with survival following septal myectomy for obstructive hypertrophic cardiomyopathy. JACC Heart Fail 10:831\u2013837","journal-title":"JACC Heart Fail"},{"key":"2489_CR15","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1161\/01.CIR.0000162460.36735.71","volume":"111","author":"A Woo","year":"2005","unstructured":"Woo A, Williams WG, Choi R, Wigle ED, Rozenblyum E, Fedwick K, Siu S, Ralph-Edwards A, Rakowski H (2005) Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy. Circulation 111:2033\u20132041","journal-title":"Circulation"},{"key":"2489_CR16","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.echo.2005.06.011","volume":"18","author":"H Yang","year":"2005","unstructured":"Yang H, Woo A, Monakier D, Jamorski M, Fedwick K, Wigle ED, Rakowski H (2005) Enlarged left atrial volume in hypertrophic cardiomyopathy: a marker for disease severity. J Am Soc Echocardiogr 18:1074\u20131082","journal-title":"J Am Soc Echocardiogr"},{"key":"2489_CR17","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/S0735-1097(00)00767-1","volume":"36","author":"NM Lakkis","year":"2000","unstructured":"Lakkis NM, Nagueh SF, Dunn JK, Killip D, Spencer WH (2000) Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: one-year follow-up. J Am Coll Cardiol 36:852\u2013855","journal-title":"J Am Coll Cardiol"},{"key":"2489_CR18","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1161\/CIRCULATIONAHA.107.738740","volume":"118","author":"P Sorajja","year":"2008","unstructured":"Sorajja P, Valeti U, Nishimura RA, Ommen SR, Rihal CS, Gersh BJ, Hodge DO, Schaff HV, Holmes DR (2008) Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation 118:131\u2013139","journal-title":"Circulation"},{"key":"2489_CR19","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1161\/CIRCINTERVENTIONS.110.959718","volume":"4","author":"MK Jensen","year":"2011","unstructured":"Jensen MK, Almaas VM, Jacobsson L, Hansen PR, Havndrup O, Aakhus S, Svane B, Hansen TF, K\u00f8ber L, Endresen K, Eriksson MJ, J\u00f8rgensen E, Amlie JP, Gadler F, Bundgaard H (2011) Long-term outcome of percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: a Scandinavian multicenter study. Circ Cardiovasc Interv 4:256\u2013265","journal-title":"Circ Cardiovasc Interv"},{"key":"2489_CR20","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.1016\/j.jacc.2018.09.064","volume":"72","author":"A Batzner","year":"2018","unstructured":"Batzner A, Pfeiffer B, Neugebauer A, Aicha D, Blank C, Seggewiss H (2018) Survival after alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 72:3087\u20133094","journal-title":"J Am Coll Cardiol"},{"key":"2489_CR21","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.jtcvs.2018.08.062","volume":"157","author":"A Nguyen","year":"2019","unstructured":"Nguyen A, Schaff HV, Hang D, Nishimura RA, Geske JB, Dearani JA, Lahr BD, Ommen SR (2019) Surgical myectomy versus alcohol septal ablation for obstructive hypertrophic cardiomyopathy: a propensity score-matched cohort. J Thorac Cardiovasc Surg 157:306-315.e3","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2489_CR22","first-page":"1161","volume":"64","author":"J Veselka","year":"2006","unstructured":"Veselka J (2006) Pressure gradient response after alcohol septal ablation in hypertrophic obstructive cardiomyopathy. Kardiol Pol 64:1161\u20131162","journal-title":"Kardiol Pol"},{"key":"2489_CR23","first-page":"358","volume":"1","author":"L Faber","year":"2005","unstructured":"Faber L, Welge D, Fassbender D, Buschler H, Schmidt HK, Horstkotte D (2005) Percutaneous septal ablation in hypertrophic obstructive cardiomyopathy: current status. EuroIntervention 1:358\u2013366","journal-title":"EuroIntervention"},{"key":"2489_CR24","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1016\/j.amjcard.2010.07.017","volume":"106","author":"J Yuan","year":"2010","unstructured":"Yuan J, Qiao S, Zhang Y, You S, Duan F, Hu F, Yang W (2010) Follow-up by cardiac magnetic resonance imaging in patients with hypertrophic cardiomyopathy who underwent percutaneous ventricular septal ablation. Am J Cardiol 106:1487\u20131491","journal-title":"Am J Cardiol"},{"key":"2489_CR25","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1253\/circj.CJ-20-1191","volume":"85","author":"J Matsuda","year":"2021","unstructured":"Matsuda J, Takano H, Morooka M, Imori Y, Nakata J, Kitamura M, Tara S, Tokita Y, Yamamoto T, Takayama M, Shimizu W (2021) Relationship between procedural right bundle branch block and 1-year outcome after alcohol septal ablation for hypertrophic obstructive cardiomyopathy - a retrospective study -. Circ J 85:1481\u20131491","journal-title":"Circ J"},{"key":"2489_CR26","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1093\/eurheartj\/ehv693","volume":"37","author":"J Veselka","year":"2016","unstructured":"Veselka J, Jensen MK, Liebregts M, Januska J, Krejci J, Bartel T, Dabrowski M, Hansen PR, Almaas VM, Seggewiss H, Horstkotte D, Tomasov P, Adlova R, Bundgaard H, Steggerda R, Ten Berg J, Faber L (2016) Long-term clinical outcome after alcohol septal ablation for obstructive hypertrophic cardiomyopathy: results from the Euro-ASA registry. Eur Heart J 37:1517\u20131523","journal-title":"Eur Heart J"},{"key":"2489_CR27","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.jacc.2017.02.080","volume":"70","author":"M Liebregts","year":"2017","unstructured":"Liebregts M, Vriesendorp PA, Ten Berg JM (2017) Alcohol septal ablation for obstructive hypertrophic cardiomyopathy: a word of endorsement. J Am Coll Cardiol 70:481\u2013488","journal-title":"J Am Coll Cardiol"},{"key":"2489_CR28","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1056\/NEJMoa021332","volume":"348","author":"MS Maron","year":"2003","unstructured":"Maron MS, Olivotto I, Betocchi S, Casey SA, Lesser JR, Losi MA, Cecchi F, Maron BJ (2003) Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 348:295\u2013303","journal-title":"N Engl J Med"},{"key":"2489_CR29","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1007\/s00380-023-02295-0","volume":"38","author":"Y Hen","year":"2023","unstructured":"Hen Y, Otaki Y, Iguchi N, Takara A, Takada K, Kanisawa M, Machida H, Inoue K, Takamisawa I, Takayama M (2023) High-risk imaging characteristics in left ventricular apex for the life-threatening arrhythmic events in Japanese hypertrophic cardiomyopathy patients. Heart Vessels 38:1442\u20131450","journal-title":"Heart Vessels"},{"key":"2489_CR30","doi-asserted-by":"publisher","first-page":"f198","DOI":"10.1093\/europace\/eux251","volume":"20","author":"M Liebregts","year":"2018","unstructured":"Liebregts M, Faber L, Jensen MK, Vriesendorp PA, Hansen PR, Seggewiss H, Horstkotte D, Adlova R, Michels M, Bundgaard H, Ten Berg JM, Veselka J (2018) Validation of the HCM risk-SCD model in patients with hypertrophic cardiomyopathy following alcohol septal ablation. Europace 20:f198\u2013f203","journal-title":"Europace"},{"key":"2489_CR31","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.amjcard.2022.08.028","volume":"184","author":"J Veselka","year":"2022","unstructured":"Veselka J, Liebregts M, Cooper R, Faber L, Januska J, Kashtanov M, Tesarkova KH, Hansen PR, Seggewiss H, Shloydo E, Popov K, Hansvenclova E, Polakova E, Ten Berg J, Stables RH, Jarkovsky J, Bonaventura J (2022) Prediction of sudden cardiac arrest after alcohol septal ablation for hypertrophic obstructive cardiomyopathy: ASA-SCARRE risk score. Am J Cardiol 184:120\u2013126","journal-title":"Am J Cardiol"},{"key":"2489_CR32","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1016\/j.jacc.2011.06.073","volume":"58","author":"SF Nagueh","year":"2011","unstructured":"Nagueh SF, Groves BM, Schwartz L, Smith KM, Wang A, Bach RG, Nielsen C, Leya F, Buergler JM, Rowe SK, Woo A, Maldonado YM, Spencer WH (2011) Alcohol septal ablation for the treatment of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 58:2322\u20132328","journal-title":"J Am Coll Cardiol"},{"key":"2489_CR33","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1016\/j.jacc.2022.02.032","volume":"79","author":"H Cui","year":"2022","unstructured":"Cui H, Schaff HV, Wang S, Lahr BD, Rowin EJ, Rastegar H, Hu S, Eleid MF, Dearani JA, Kimmelstiel C, Maron BJ, Nishimura RA, Ommen SR, Maron MS (2022) Survival following alcohol septal ablation or septal myectomy for patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 79:1647\u20131655","journal-title":"J Am Coll Cardiol"},{"key":"2489_CR34","unstructured":"Vital Statistics. The Japanese Ministry of Health, Labour and Welfare. https:\/\/www.mhlw.go.jp\/toukei\/saikin\/hw\/jinkou\/geppo\/nengai23\/dl\/gaikyouR5.pdf [Accessed 25 Sept 2024.]"},{"key":"2489_CR35","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1253\/circj.66.323","volume":"66","author":"A Matsumori","year":"2002","unstructured":"Matsumori A, Furukawa Y, Hasegawa K, Sato Y, Nakagawa H, Morikawa Y, Miura K, Ohno Y, Tamakoshi A, Inaba Y, Sasayama S, Co-research workers (2002) Epidemiologic and clinical characteristics of cardiomyopathies in Japan: results from nationwide surveys. Circ J 66:323\u2013336","journal-title":"Circ J"},{"key":"2489_CR36","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1253\/circj.CJ-17-0845","volume":"82","author":"T Kubo","year":"2018","unstructured":"Kubo T, Hirota T, Baba Y, Ochi Y, Takahashi A, Yamasaki N, Hamashige N, Yamamoto K, Kondo F, Bando K, Yamada E, Furuno T, Yabe T, Doi YL, Kitaoka H (2018) Patients\u2019 characteristics and clinical course of hypertrophic cardiomyopathy in a regional Japanese cohort-results from Kochi RYOMA study. Circ J 82:824\u2013830","journal-title":"Circ J"},{"key":"2489_CR37","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/clc.23113","volume":"42","author":"M Osman","year":"2019","unstructured":"Osman M, Kheiri B, Osman K, Barbarawi M, Alhamoud H, Alqahtani F, Alkhouli M (2019) Alcohol septal ablation vs myectomy for symptomatic hypertrophic obstructive cardiomyopathy: systematic review and meta-analysis. Clin Cardiol 42:190\u2013197","journal-title":"Clin Cardiol"},{"key":"2489_CR38","doi-asserted-by":"publisher","first-page":"ezad043","DOI":"10.1093\/ejcts\/ezad043","volume":"63","author":"Y Yokoyama","year":"2023","unstructured":"Yokoyama Y, Shimoda T, Shimada YJ, Shimamura J, Akita K, Yasuda R, Takayama H, Kuno T (2023) Alcohol septal ablation versus surgical septal myectomy of obstructive hypertrophic cardiomyopathy: systematic review and meta-analysis. Eur J Cardiothorac Surg 63:ezad043","journal-title":"Eur J Cardiothorac Surg"},{"key":"2489_CR39","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1016\/j.jacc.2021.07.065","volume":"78","author":"AM Dybro","year":"2021","unstructured":"Dybro AM, Rasmussen TB, Nielsen RR, Andersen MJ, Jensen MK, Poulsen SH (2021) Randomized trial of metoprolol in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 78:2505\u20132517","journal-title":"J Am Coll Cardiol"},{"key":"2489_CR40","doi-asserted-by":"publisher","first-page":"4832","DOI":"10.1002\/ehf2.13672","volume":"8","author":"M Hamada","year":"2021","unstructured":"Hamada M, Shigematsu Y, Ikeda S, Ohshima K, Ogimoto A (2021) Impact of cibenzoline treatment on left ventricular remodelling and prognosis in hypertrophic obstructive cardiomyopathy. ESC Heart Fail 8:4832\u20134842","journal-title":"ESC Heart Fail"},{"key":"2489_CR41","volume":"49","author":"H Hn\u00e1tov\u00e1","year":"2023","unstructured":"Hn\u00e1tov\u00e1 H, Ful\u00ednov\u00e1 K, \u0158ih\u00e1kov\u00e1 B, Bonaventura J, Veselka J (2023) Effect of metoprolol in hypertrophic obstructive cardiomyopathy patients after alcohol septal ablation. Int J Cardiol Heart Vasc 49:101317","journal-title":"Int J Cardiol Heart Vasc"},{"key":"2489_CR42","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","volume":"80","author":"MY Desai","year":"2022","unstructured":"Desai MY, Owens A, Geske JB, Wolski K, Naidu SS, Smedira NG, Cremer PC, Schaff H, McErlean E, Sewell C, Li W, Sterling L, Lampl K, Edelberg JM, Sehnert AJ, Nissen SE (2022) Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy. J Am Coll Cardiol 80:95\u2013108","journal-title":"J Am Coll Cardiol"},{"key":"2489_CR43","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","volume":"396","author":"I Olivotto","year":"2020","unstructured":"Olivotto I, Oreziak A, Barriales-Villa R, Abraham TP, Masri A, Garcia-Pavia P, Saberi S, Lakdawala NK, Wheeler MT, Owens A, Kubanek M, Wojakowski W, Jensen MK, Gimeno-Blanes J, Afshar K, Myers J, Hegde SM, Solomon SD, Sehnert AJ, Zhang D, Li W, Bhattacharya M, Edelberg JM, Waldman CB, Lester SJ, Wang A, Ho CY, Jacoby D (2020) Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 396:759\u2013769","journal-title":"Lancet"},{"key":"2489_CR44","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1016\/j.jacc.2020.03.064","volume":"75","author":"CY Ho","year":"2020","unstructured":"Ho CY, Mealiffe ME, Bach RG, Bhattacharya M, Choudhury L, Edelberg JM, Hegde SM, Jacoby D, Lakdawala NK, Lester SJ, Ma Y, Marian AJ, Nagueh SF, Owens A, Rader F, Saberi S, Sehnert AJ, Sherrid MV, Solomon SD, Wang A, Wever-Pinzon O, Wong TC, Heitner SB (2020) Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 75:2649\u20132660","journal-title":"J Am Coll Cardiol"},{"key":"2489_CR45","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1056\/NEJMoa2401424","volume":"390","author":"MS Maron","year":"2024","unstructured":"Maron MS, Masri A, Nassif ME, Barriales-Villa R, Arad M, Cardim N, Choudhury L, Claggett B, Coats CJ, D\u00fcngen HD, Garcia-Pavia P, Hag\u00e8ge AA, Januzzi JL, Lee MMY, Lewis GD, Ma CS, Michels M, Olivotto I, Oreziak A, Owens AT, Spertus JA, Solomon SD, Tfelt-Hansen J, van Sinttruije M, Veselka J, Watkins H, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Meng L, Wohltman A, Abraham TP (2024) Aficamten for symptomatic obstructive hypertrophic cardiomyopathy. N Engl J Med 390:1849\u20131861","journal-title":"N Engl J Med"}],"container-title":["Heart and Vessels"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-024-02489-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00380-024-02489-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-024-02489-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T19:02:35Z","timestamp":1747508555000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00380-024-02489-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,24]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["2489"],"URL":"https:\/\/doi.org\/10.1007\/s00380-024-02489-0","relation":{},"ISSN":["0910-8327","1615-2573"],"issn-type":[{"value":"0910-8327","type":"print"},{"value":"1615-2573","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,24]]},"assertion":[{"value":"16 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.Ethical approvalEthics approval for the study was obtained from the Review Committee of Nippon Medical School (approval number B-2022\u2013529). The study was performed in accordance with the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Written informed consent was obtained from all patients according to the principles of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}